Jonathan M. Cohen - 03 Mar 2026 Form 4 Insider Report for 20/20 Biolabs, Inc.

Reporting relationship: Chief Executive Officer, Director, 10%+ Owner
Issuer ticker: AIDX on Nasdaq
Reported as of: 03 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Mar 2026, 17:48:56 UTC
Prior SEC filing: 19 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Cohen

Key filing fact

Jonathan M. Cohen filed Form 4 for 20/20 Biolabs, Inc. on 04 Mar 2026.

Key facts

This page summarizes Jonathan M. Cohen's Form 4 filing for 20/20 Biolabs, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Mar 2026, 17:48.

Change

Previous filing in this sequence was filed on 19 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002111543 Primary reporting owner

Cohen Jonathan M

Relationship: Chief Executive Officer, Director, 10%+ Owner
Address: C/O 20/20 BIOLABS, INC. 15810 GAITHER RD, SUITE 235, GAITHERSBURG
Signature: /s/ Jonathan Cohen
Signature date: 04 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

No ticker transaction Derivative

Stock Option

Award

Transaction value
Shares: +352,936
Change %
Price: $0.000000^*
Shares after: 352,936
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 352,936
Exercise price: $3.39
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On March 3, 2026, the Reporting Person was granted a stock option for the purchase of 352,936 shares of common stock, which shall vest in equal quarterly installments over the following four (4) years, subject to the Reporting Person's continuous service to the Issuer.